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Prostaglandins (PGs) are lipid mediators that participate in the regulation of immunological and inflammatory responses, and PG
production can affect viral replication. In this study, we have investigated the mechanism of PGE2 production in airway epithelial cells,
following respiratory syncytial virus (RSV) infection, and its role in viral replication. We show that RSV infection strongly induces PGE2
secretion, in a time- and replication-dependent manner, through increased cyclooxygenase-2 (COX-2) expression, which occurs
independently from viral or cellular protein synthesis. RSV infection induces arachidonic acid release through induction of cytoplasmic
phospholipase A2 (cPLA2) enzymatic activity and its membrane translocation. Specific inhibitors of cPLA2 significantly block RSV-induced
PGE2 secretion, indicating a key role of cPLA2 in viral-induced PG production. Blocking PG secretion, through cPLA2 or COX-2 inhibition,
results in impairment of RSV replication and subsequent RSV-mediated epithelial cell responses, suggesting that inhibition of PG secretion
could be beneficial in RSV infection by reducing proinflammatory mediator production.
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Prostaglandins (PGs) are ubiquitous fatty acid derivatives
produced by a variety of tissues and cell types and
participate in the regulation of both physiological and
pathophysiological processes. Normal physiological pro-
cesses include regulation of renal function, vasomotor tone,
platelet aggregation and blood clotting, differentiation of
immune cells, wound healing, nerve growth, bone metab-
olism, ovulation, and initiation of labor. Prostaglandins also
participate in the regulation of immunological and inflam-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: ancasola@utmb.edu (A. Casola).matory responses. Production of prostaglandin E2 (PGE2) is
markedly increased in response to a variety of stimuli
including interleukin-1 (IL-1), tumor necrosis factor
(TNF)a, antigen/antibody complexes, lipopolysaccharide
(LPS), and infectious agents (Arias-Negrete et al., 1995;
Corbett et al., 1993; Steer et al., 2003). PGE2 often plays an
immunosuppressive role during inflammatory responses,
thus preventing overactivation of cellular immunity. For
example, PGE2 is able to inhibit cytokine production, as
well as T and B cell proliferation (Phipps et al., 1991). A
variety of DNA and RNA viruses have been shown to
stimulate PGE2 production through cyclooxygenase
(COX)-2 expression (Bartz et al., 2002; Nokta et al.,
1996; Rossen et al., 2004), although certain viruses, like
Epstein–Barr virus, have been shown to suppress PGE2
secretion and COX-2 mRNA accumulation (Savard et al.,005) 12 – 24
T. Liu et al. / Virology 343 (2005) 12–24 132000). Respiratory syncytial virus (RSV), an enveloped
negative-sense single-stranded RNA virus (Hall and McCar-
thy, 1995), is a leading cause of epidemic respiratory tract
illness in children in the US and worldwide, resulting in
more than 100,000 hospital admissions annually in the US
alone (Hall and McCarthy, 1995). RSV infection results in
the production of a variety of mediators involved in lung
immune/inflammatory responses, like cytokines, chemo-
kines, interferons, and upregulating adhesion molecules and
MHC antigens on the surface of infected cells (reviewed in
Garofalo and Haeberle, 2000). Though RSV infection of the
lung results in profound airway inflammation, it is not
associated with robust and long-lasting immunological
responses so that re-infection is common throughout life
(Garofalo and Ogra, 1996). Indeed, RSV infection has been
shown to inhibit mononuclear cell responses, as well as
lymphocyte proliferation (Franke et al., 1995; Keles et al.,
1999), possibly through PGE2 production (Keles et al.,
1998, 1999). RSV induction of PGE2 was demonstrated by
infecting human cord blood macrophages (Midulla et al.,
1993) and dendritic cells (Bartz et al., 2002). When
compared with influenza and parainfluenza virus, RSV
was the strongest PGE2 inducer. In vivo studies, either in
cattle experimentally infected with bovine RSV (Gershwin
et al., 1989) or in infants positive for RSV infection (Sznajer
et al., 2004), have also shown increased levels of PGE2 in
the plasma or endotracheal aspirates. Recently, Richardson
et al. have shown PGE2 production and COX-2 expression
in alveolar epithelial cells infected with RSV, as well as in
the lungs of RSV-infected cotton rats (Richardson et al.,
2005). The latter study, however, did not address in depth
the mechanism of RSV-induced PGE2 prostaglandin secre-
tion and did not investigate the effect of inhibition of PGE2
production on RSV replication. Indeed, increased produc-
tion of PGE2 has been shown to result in increased
replication of many different types of viruses, including
herpes, adenovirus, picorna viruses, and HIV, although
PGE2 can inhibit viral replication of a few ones, such as
adenovirus, parainfluenza, and measles (reviewed in Steer et
al., 2003). In this study, we show that alveolar epithelial
cells are strong producers of PGE2 following RSV infection,
in a time- and replication-dependent manner, through COX-
2 mRNA expression and protein synthesis. RSV-induced
COX-2 expression does not require either viral or cellular
protein synthesis as it occurs in the presence of cyclo-
heximide, an inhibitor of protein translation. RSV infection
of airway epithelial cells induces arachidonic acid (AA)
release by activation of cytoplasmic phospholipase A2
(cPLA2), and specific inhibitors of cPLA2 significantly
block RSV-induced PGE2 secretion in A549 cells, indicat-
ing a key role of cPLA2 in viral-induced prostaglandin
production. Inhibition of PGE2 secretion, using either
specific COX-2 or cPLA2 inhibitors, results in significant
impairment of RSV replication and therefore RSV-mediated
airway epithelial cell responses, such as chemokine pro-
duction, as well as transcription factor activation, suggestingthat selective inhibition of PGE2 could be beneficial in RSV
infection by dampening the secretion of proinflammatory
mediators and possibly promoting stronger immunological
responses.Results
RSV infection induces PGE2 secretion through COX-2
expression in A549 cells
We and others have previously shown that airway
epithelial cells, the target cells of RSV infection, play an
important role in initiating mucosal immune/inflammatory
responses by producing a variety of soluble factors, like
cytokines, chemokines, interferons, etc., that regulate com-
munication among cells of the immune system (Garofalo and
Haeberle, 2000). Since PGE2 levels have been shown to be
elevated in children with severe RSV infection (Sznajer et al.,
2004), we investigated whether A549 cells, a lung carcinoma
cell line that retains features of type II alveolar epithelial cells
(Lieber et al., 1976; Smith, 1977), were able to produce PGE2
following RSV infection. A549 cells is a widely accepted
model for studying RSV–epithelial cell interactions (Fiedler
et al., 1996; Garofalo et al., 1996; Jamaluddin et al., 1998),
and we have previously shown that these cells behave very
similar to normal human airway epithelial cells, such as the
small alveolar epithelial cells, in terms of chemokine/
cytokine gene expression, transcription factor, and signaling
pathway activation following RSV infection (Garofalo et al.,
1996; Olszewska-Pazdrak et al., 1998; Casola et al., 2001a;
Zhang et al., 2001; Pazdrak et al., 2002). A549 cells were
infected with purified RSV, and culture supernatants were
harvested at different time post-infection (p.i.) to determine
PGE2 secretion by ELISA. As shown in Fig. 1A, RSV
exposure resulted in a time-dependent increased production
of PGE2, starting as early as 6 h p.i., withmaximal production
at 36 h p.i., time after which infected cells started to loose
viability. Addition of UV-inactivated virus, which is unable to
replicate, did not induce PG production (data not shown).
The first event in eicosanoid production is the release of
arachidonic acid (AA) by PLA2. COX enzymes catalyze the
oxidation of AA to PGH2 which is then isomerized to
various prostanoids, including PGE2. There are three known
isoforms of COX (reviewed in Smith et al., 2000). COX-1
and COX-2 are similar in size, substrate specificity, and
kinetics but differ in distribution and expression. COX-1 is
constitutively expressed by many cell types, and PGs
produced by this isoform are involved in the regulation of
several normal physiological functions (Smith et al., 2000).
While COX-2 is constitutively expressed in certain organs
or tissues, such as brain, kidney, and testes, in most cell
types, its expression is rapidly upregulated by a variety of
stimuli, and it is responsible for inducible PG secretion
(Smith et al., 2000). Therefore, to determine whether
increased PGE2 release was dependent on COX-2 activa-
Fig. 1. PGE2 production in A549 cells infected with RSV. (A) Time course: A549 cells were infected with RSV, and, at various time points after infection,
culture supernatants from control and infected cells were assayed for PGE2 production by ELISA. (B) Effect of COX-2 inhibitors on PGE2 secretion. A549
cells were infected with RSV in the absence or presence of various doses of either celecoxib or NS398. Culture supernatants, from control and infected cells,
were assayed 24 h later for PGE2 production. Data are expressed as mean T standard deviation of two independent experiments performed in triplicates.
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absence or presence of various concentrations of two
different COX-2 inhibitors, celecoxib and NS398 (Penning
et al., 1997; Futaki et al., 1994). Supernatants were then
assayed for PGE2 secretion by ELISA. As shown in Fig.
1B, addition of 10 and 50 AM of either celecoxib or NS398
at the time of RSV infection completely blocked PGE2
production, indicating that COX-2 is the major enzyme
responsible for viral-induced PGE2 secretion.
To determine whether COX-2 expression was induced in
alveolar epithelial cells infected with RSV, total RNA was
extracted from control and infected A549 cells at different
times post-infection for analysis of steady-state level of
COX-2 mRNA by Northern blot. A small increase in
mRNA expression was first detected at 6 h p.i., with
maximal induction at 24 h (Fig. 2A). There was no further
increase in mRNA levels at later time points (data not
shown). The upregulation of COX-2 mRNA was paralleled
by an increase in COX-2 protein synthesis, investigated by
Western blot analysis (Fig. 2B), indicating that COX-2 gene
expression and protein synthesis are coupled in RSV-
infected A549 cells. RSV infection of A549 cells is known
to induce the release of cytokines, such as IL-1 and TNF
(Patel et al., 1995), which can affect COX-2 expression
(Seibert et al., 1995). To determine whether a solublemediator or RSV replication directly was responsible for
COX-2 induction, we assessed COX-2 expression in A549-
infected cells treated with cycloheximide, a protein trans-
lation inhibitor, which blocks both viral and cellular protein
synthesis. As shown in Fig. 2C, RSV infection of A549 cells
induced a 7-fold increase in COX-2 mRNA levels,
compared to control cells, which was greatly enhanced by
the presence of cycloheximide. These findings indicate that
viral transcription/replication alone is sufficient to induce
COX-2 expression and that neither viral nor cellular protein
synthesis is required.
RSV infection induces AA release and cPLA2 activation in
alveolar epithelial cells
Since the precursor for PGE2 synthesis is AA, we
determined whether RSV induced an increased release of
AA from infected cells. A549 cells were labeled overnight
with [3H]AA and then infected with RSV for various
lengths of time. Supernatants from control and infected cells
were collected to determine total radioactivity released into
the medium by scintillation counting. As shown in Fig. 3,
RSV-infected cells showed a significantly higher release of
radiolabeled AA compared to control cells, suggesting
phospholipase activation.
Fig. 3. AA release from RSV-infected cells. A549 cells were labeled with
[3H]AA for 15 h, and, after extensive washing, cells were infected with
RSV. Supernatants from control and infected cells were collected at
different time points after infection, and amount of radioactivity released
into the medium was determined by scintillation counting. The experiment
was performed in triplicate and repeated twice. Results are expressed as
percent increase over control cells.
Fig. 4. Effect of various PLA2 inhibitors on RSV-induced PGE2 production.
A549 cells were infected with RSV in the absence or presence of 10 AM
BPB, 25 AM MAPF, or 25 AM pyrrophenone (PP). Culture supernatants,
from control and infected cells, were assayed 24 h later for PGE2 secretion
by ELISA. Data are expressed as mean T standard deviation of three
independent experiments performed in triplicates.
Fig. 2. COX-2 expression in RSV-infected alveolar epithelial cells. (A)
Northern blot. A549 cells were infected with RSV for various lengths of
time. Total RNA was extracted from control and infected cells, and twenty
micrograms of RNA was fractionated on a 1.2% agarose– formaldehyde
gel, transferred to nylon membrane, and hybridized to a radiolabeled COX-
2 cDNA probe. Membrane was stripped and reprobed with h-actin to verify
equal loading of the samples. (B) Western blot. Total cell lysates were
prepared from control and A549 cells infected for various lengths of time,
fractionated on a 10% SDS-PAGE, transferred to PVDF membranes, and
probed with the appropriate antibody. Membrane was stripped and reprobed
with h-actin to verify equal loading of the samples. (C) Q-RT-PCR. A549
cells were infected with RSV for 24 h in the presence or absence of 20 AM
cycloheximide. Total RNA was extracted from control and infected cells,
and COX-2 mRNA levels were analyzed by real-time PCR. Signals were
normalized to 18S RNA (see Materials and methods). Values are expressed
as fold increase over control cells.
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cells and tissues. Using functional criteria, PLA2 are
classified in three main types: secretory PLA2 (sPLA2),
intracellular Ca2+-dependent PLA2 (cPLA2), and intracel-
lular Ca2+-independent PLA2 (iPLA2) (reviewed in Steer et
al., 2003; Balsinde et al., 1999). While intracellular iPLA2
seems to be mainly involved in membrane phospholipid
remodeling, sPLA2 and cPLA2 release AA as precursor of
the inflammatory eicosanoids. In cell types that lack sPLA2
expression, cPLA2 accounts for the vast majority of AArelease during cellular activation and is the enzyme involved
in receptor-activated signaling (Steer et al., 2003). To
determine whether cPLA2 was involved in RSV-induced
PGE2 production, we treated airway epithelial cells with
various inhibitors, which block either sPLA2, both cPLA2
and iPLA2, or cPLA2 only. We then assessed PGE2
production at 24 h p.i. As shown in Fig. 4, both MAPF, a
specific inhibitor of cPLA2 and iPLA2 (Balsinde et al.,
1999), and pyrrophenone, a recently characterized cPLA2
specific inhibitor (Ono et al., 2002; Seno et al., 2000),
greatly reduced RSV-induced PGE2 secretion, which was
not affected by BPB, an inhibitor of sPLA2 (Balsinde et al.,
1999), indicating that this enzyme is not involved in RSV-
induced PGE2 production.
Table 1
Viral titers in supernatants of A549 cells infected with RSV for 48 h in the
presence or absence of various inhibitors.
Treatment Viral titer (pfu/ml)
– 7.3 T 0.5  106
DMSO 5 T 0.6  106
Celecoxib 1.3 T 0.3  104
Pyrrophenone 3 T 0.7  102
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investigate cPLA2 activation following RSV infection. In
unstimulated cells, cPLA2 resides mainly in the cytoplasm
but upon stimulation translocates to the membrane
compartment to release AA. To determine whether RSV
infection was able to increase cPLA2 activity, A549 were
infected with RSV for various lengths of time and
harvested to prepare cytosolic and membrane fractions.
cPLA2 activity in both fractions was determined by
quantification of the amount of free radiolabeled AA
released from sn-2-[14C]-arachidonyl phosphatidyl-ethanol-
amine. As shown in Fig. 5A, membrane fractions of RSV-
infected cells showed a time-dependent induction of
cPLA2 activity, with a three-fold increase at 12 and 24 h
p.i., a kinetic similar to the time course of AA release from
infected radiolabeled cells (Fig. 3). There was no
significant change of cPLA2 activity in the cytosolic
fraction of infected cells (data not shown).
To investigate cPLA2 membrane translocation, following
RSV infection, we performed Western blot analysis of
cytosolic and membrane proteins. There was a time-
dependent increase in cPLA2 abundance in the membrane
fraction, which was paralleled by a decrease in cytosolic
protein abundance (Fig. 5B). These data confirm cPLA2
activation following RSV infection.Fig. 5. cPLA2 activation following RSV infection. (A) Enzymatic activity.
Membrane proteins were prepared from control and A549 cells infected for
various lengths of time and assayed for PLA2 enzymatic activity, as
described in Materials and methods. (B) Western blot. Cytoplasmic and
membrane proteins were prepared from control and A549 cells infected for
various lengths of time, fractionated on a 10% SDS-PAGE, transferred to
PVDF membranes, and probed with anti-cPLA2 antibody. Membranes were
stripped and reprobed with either h-actin or h-catenin to verify equal
loading of the samples.Inhibition of cPLA2 and COX-2 induction affects RSV
replication and viral-induced cellular responses
Most viruses modify the host cellular environment in
order to maximize their replication. Since PGE2 production
has been shown to affect replication of other viruses, often
resulting in enhanced infection, we investigated whether
inhibition of COX-2 or the upstream activator cPLA2 would
modify RSV replication in alveolar epithelial cells. A549
were infected with RSV in the presence or absence of either
50 AM celecoxib or 25 AM pyrrophenone, and viral titers
were determined 48 h post-infection. Production of infec-
tious particles, defined as pfu/ml, was significantly
decreased by both celecoxib and pyrrophenone treatment
(Table 1), indicating that PGE2 plays an important role in
RSV replication. Vehicle treatment slightly reduced cell
viability (a decrease of ¨5–10% in DMSO-treated cells
versus untreated, data not shown) without significantly
reducing the amount of virus released by infected cells.
Similar results were obtained when the inhibitors were
added at the end of viral adsorption to the cells (data not
shown). To determine whether reduced viral replication was
in part due to inhibition of viral transcription, we assessed
RSV N protein gene expression in A549 cells infected with
RSV in the presence of either 50 AM celecoxib or 25 AM
pyrrophenone. As shown in Fig. 6, a 1.1 kb RSV N
transcript was strongly present in A549 cells infected with
RSV at 12 h p.i., and it was reduced more than 90% by
pyrrophenone treatment (panel A) and 70–80% by cele-
coxib treatment (panel B), indicating that PG production is
necessary for efficient viral replication.
We have previously shown that RSV infection of A549
cells induces increased production of chemokines, important
proinflammatory mediators, in a dose- and time-dependent
manner, which requires viral replication (Olszewska-Pazdrak
et al., 1998; Zhang et al., 2001). To determine whether
inhibition of RSV-induced COX-2 activation affected che-
mokine production from infected epithelial cells, we inves-
tigated CC and CXC chemokine mRNA steady-state levels in
A549 cells infected with RSV for 12 h, in the absence or
presence of celecoxib. RANTES and MCP-1, prototypes of
CC chemokines, as well as IL-8, a prototype of CXC
chemokine, were highly induced by RSV infection and
significantly reduced by the COX-2 inhibitor (Figs. 7A and
B). Similarly, RANTES and IL-8 protein secretion were also
significantly inhibited by celecoxib treatment, as shown in
Fig. 7C.
Fig. 6. Effect of COX-2 inhibition on RSVreplication. A549 cells were infected with RSV for 12 h in the absence or presence of either 25 AMpyrrophenone (A) or
50 AM celecoxib (B). INH indicates the presence of the inhibitor. Twenty micrograms of RNA extracted from control and cells infected with RSV for 15 h were
fractionated on a 1.2% agarose– formaldehyde gel, transferred to nylon membrane, and hybridized to a radiolabeled RSV N protein cDNA probe. Membranes
were stripped and hybridized with a radiolabeled h-actin probe to show equal loading of the samples.
Fig. 7. Effect of COX-2 inhibition on RSV-induced chemokine production. (A) RPA. A549 cells were infected with RSV for 12 h in the absence or presence of
50 AM celecoxib. Total RNAwas extracted from control and infected cells, and two micrograms of RNAwas used for RPA. (B) Densitometric analysis of RSV-
induced chemokine mRNA levels expressed as fold increase over uninfected cells. Solid bars represent RSValone, open bars RSV plus celecoxib. (C) ELISA.
A549 cells were infected with RSV in the absence or presence of 50 AM celecoxib (INH). Culture supernatants, from control and infected cells, were assayed
24 h later for IL-8 and RANTES production. Data are expressed as mean T standard deviation of three independent experiments performed in triplicates.
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Fig. 8. Effect of COX-2 inhibitor on RSV-induced IRF and NF-nB
activation. Nuclear extracts were prepared from control and cells infected
with RSV for 12 h, in the absence or presence of 50 AM celecoxib (INH),
and used for binding to either the RANTES ISRE or the IL-8 NF-nB site in
EMSA. Shown are the nucleoprotein complexes formed on the RANTES
ISRE or on the IL-8 NF-nB sites in response to RSV infection.
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mechanisms involved in RSV-induced expression of the
chemokines IL-8 and RANTES (Garofalo et al., 1996;
Casola et al., 2000, 2001b). Gene transcription of both
chemokines is dependent on an intact nuclear factor (NF)-
nB signaling pathway, as we and others have previously
shown (Garofalo et al., 1996; Casola et al., 2001b; Tian et
al., 2002). RSV-induced RANTES expression is also
dependent on the activation of interferon regulatory factors
(IRFs) which are absolutely necessary for RANTES gene
transcription (Garofalo et al., 1996; Casola et al., 2001b). To
investigate whether COX-2 inhibition would affect NF-nB
and IRF activation, we infected A549 cells with RSV in the
presence or absence of celecoxib, and we determined the
abundance of DNA-binding proteins recognizing either the
IL-8 NF-nB site or the RANTES IRF binding site (also
known as ISRE). As shown in Fig. 8, induction of the
nucleoprotein complex formed on the ISRE probe, follow-
ing RSV infection, was completely abrogated by celecoxib
treatment, while the complex formed on the NF-nB probe
was reduced by 70%, in agreement with the reduced IL-8
and RANTES gene expression and protein secretion
observed, following inhibition of COX-2.Discussion
RSV is the leading cause of epidemic respiratory tract
illness in children in the US and worldwide. In infants and
young children, RSV is the most common etiologic agent of
bronchiolitis, a syndrome characterized by wheezing, dysp-
nea, respiratory distress, and the radiological evidence of
hyperaeration of the lung. RSV infection does not induce
protective immunity, resulting in repeat attacks of acute
respiratory tract illness through adulthood. Indeed, RSV
infection has been shown to inhibit mononuclear cellresponses, as well as lymphocyte proliferation (Franke et
al., 1995; Keles et al., 1999). In addition to acute morbidity,
there are long-term consequences of RSV infection in
infancy. RSV has been shown to predispose to the develop-
ment of hyperreactive airway disease, and recurrent episodes
of wheezing in asthmatic children are often precipitated by
RSV infection (Holberg et al., 1991; Stein et al., 1999; Sly
and Hibbert, 1989). In prospective studies, RSV bronchiolitis
has been demonstrated to be the dominant risk factor among
those known or suspected to influence the development of
asthma (Sigurs et al., 1995).
PGE2 is a small lipid molecule known to modulate
immune functions (reviewed in Phipps et al., 1991). It
inhibits T-cell proliferation, suppresses the proliferation of
immature B-cells, and inhibits maturation of dendritic cells
and their ability to present antigen. Furthermore, PGE2 has
been implicated in the enhancement of T helper 2 (Th2)-
type responses, implying a role for PGE2 in the develop-
ment of allergy and asthma. It has been previously shown
that RSV infection of macrophages and dendritic cells can
induce PGE2 production (Midulla et al., 1993; Bartz et al.,
2002). Recently, alveolar epithelial cells, a target of RSV
infection, have been shown to be an important source of
PGE2 (Richardson et al., 2005). However, the mechanism
of RSV-induced PGE2 production and the role of PGE2 in
RSV replication and intracellular signaling were not
investigated.
Our results show that RSV is a potent inducer of PGE2 in
alveolar epithelial cells and that viral replication is required
for PGE2 secretion. These data are different from what has
been previously shown in macrophages and dendritic cells,
which both can secrete PGE2 following exposure to either
live or UV-inactivated RSV (Bartz et al., 2002). However,
these results are in agreement with Richardson et al. study,
showing that inactivation of RSV by UV exposure or
pretreatment with palivizumab, an anti-RSV-F protein
monoclonal antibody, completely blocks viral-induced
PGE2 secretion. These data are also in agreement with our
previous findings, showing that chemokine secretion and
the signaling pathways leading to their expression, in RSV-
infected epithelial cells, are dependent on viral replication
(Olszewska-Pazdrak et al., 1998; Casola et al., 2001b),
indicating different requirements between epithelial cells
and immune cells for triggering intracellular signals. RSV
infection induces a time-dependent increase of COX-2
mRNA expression and protein synthesis, which is respon-
sible for the enhanced PGE2 production in RSV-infected
alveolar epithelial cells, as demonstrated by the use of
celecoxib and NS398, specific COX-2 inhibitors that
completely block RSV-induced PGE2 secretion. PGE2
production and COX-2 mRNA expression in A549 cells
infected with RSV start at 6 h post-infection and increases
up to 36 h, time after which cells begin to loose viability.
This kinetic is different from the one recently published by
Richardson et al., which showed no increase in either COX-
2 or PGE2 in the first 24 h of infection. Possible
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multiplicity of infection (MOI) of infection (we used an
MOI of 3 to infect the majority of cells simultaneously) and
the use of a different RSV strain (we used RSV A2 versus
the Long strain used by Richardson). Our kinetics of COX-2
expression, however, is similar to RSV induction of COX-2
in vivo, where significant COX-2 mRNA accumulation was
seen in the lungs of infected cotton rats starting at 6 h post-
infection (Richardson et al., 2005). We also demonstrate that
RSV-induced COX-2 expression is dependent on viral
replication but does not require either viral or cellular
protein synthesis since inhibition of protein translation does
not block COX-2 induction following RSV infection. The
observed enhancement of COX-2 mRNA levels by the
presence of cycloheximide is a phenomenon well described
for several genes including TNF, IL-2, and IL-8, due to
various mechanisms including stabilization of mRNA tran-
scripts, inhibition of transcriptional repressors, and post-
translational modification of transcriptional activators (Efrat
et al., 1984; Osipovich et al., 1993; Roger et al., 1998). Our
result is in contrast with the findings of Richardson et al.,
showing that soluble factors, including IL-1 and TNF, are
responsible for COX-2 induction following RSV infection
(Richardson et al., 2005). Their conclusions, however, are
based on COX-2 induction following incubation of A549
cells with culture supernatants of epithelial cells infected
with RSV for 48 h, treated with neutralizing antibodies for
various cytokines. They did not attempt to block cytokine
activity in the contest of active RSV replication. We have
previously shown that UV-inactivated cell supernatant of
early RSV infection (12 h post-infection), which contains
little amount of soluble mediators, does not induce chemo-
kine secretion and transcription factor activation in A549
cells (Garofalo et al., 1996), while cell supernatants of late
RSV infection (48 h), which contains high amounts of
cytokines and interferons, can induce gene expression and
cellular activation similar to the virus itself (Jamaluddin et
al., 2001 and A. Casola, personal communication).
The production of PG begins with the release of
arachidonic acid from membrane phospholipids by PLA2.
Based on cellular localization, PLA2 enzymes can be
classified in two isoforms, secretory and cytosolic. The
cytosolic PLA2s can then be divided in two categories,
based on the requirement of calcium for the enzymatic
activity: the intracellular Ca2+-dependent PLA2 (cPLA2)
and the intracellular Ca2+-independent PLA2 (iPLA2)
(reviewed in Steer et al., 2003; Balsinde et al., 1999).
The results of our study indicate that cPLA2 is involved in
RSV-induced PGE2 production, as indicated by the almost
complete inhibition of PGE2 secretion following airway
epithelial cell treatment with pyrrophenone, a novel
compound whose inhibitory activity of cPLA2 function is
two to three orders of magnitude higher compared to the
inhibitory activity of the other PLA2s (Ono et al., 2002;
Seno et al., 2000). A growing amount of evidence has
indicated that cPLA2a contributes directly to the biosyn-thesis of eicosanoids by releasing arachidonic acid from
membrane phospholipids and is associated with various
inflammatory lung diseases, based on experiments using
cPLA2a-deficient mice (Sapirstein and Bonventre, 2000).
In these mice, eicosanoid synthesis from inflammatory
cells decreases significantly, as do allergic symptoms and
acute lung injury induced by sepsis syndrome, indicating
the contribution of cPLA2a to eicosanoid synthesis,
leading to progression of inflammation and acute lung
injury (Nagase et al., 2000; Uozumi et al., 1997).
RSV infection of A549 cells induces cPLA2 membrane
translocation and enzymatic activity starting at early time
points of infection. This is the first report that RSV activates
cPLA2. Influenza virus infection of airway epithelial cells has
also been shown to induce PGE2 production and cPLA2
phosphorylation, a post-transcriptional modification that
enhances cPLA2 enzymatic activity (Mizumura et al.,
2003). However, that study did not show directly cPLA2
activation and did not investigate its role in PG production.
Previous studies have shown that cPLA2 is present in the
cytosol of resting cells and translocates to intracellular
membranes following stimulation with a variety of agents
(reviewed in Gijon and Leslie, 1999). The nuclear envelope
has often been reported as the major membrane compartment
to which cPLA2 relocates. In our study, we did not see
increased cPLA2 enzymatic activity or protein translocation
to the nuclear membrane following RSV infection, indicating
that cPLA2 is more likely associated with the endoplasmic
reticulum or Golgi apparatus, as recently shown in A549 cells
stimulated with the calcium ionophore A23187 (Grewal et
al., 2003).
PGE2 production has been shown to be important for
efficient replication of a variety of RNA and DNA viruses.
In our study, inhibition of PGE2 production, by blocking
either COX-2 or cPLA2 activation, caused a significant
reduction in RSV replication, indicating that PGE2 is
required for effective RSV infection of airway epithelial
cells. Our result is in contrast with the recently published
study by Richardson et al., in which inhibition of COX-2
did not produce changes in viral replication, either in vitro
or in vivo (Richardson et al., 2005). Previous studies have
shown that PGE2 production can affect various steps of
viral replication, usually following virus cellular entry.
Inhibition of PGE2 production or addition of exogenous
PGE2 has been shown to modulate viral genome replication/
transcription (Allal et al., 2004; Symensma et al., 2003),
protein synthesis (Rossen et al., 2004; Ray et al., 2004), as
well as virus assembly (Ray et al., 2004). Our study
suggests that blocking either cPLA2 or COX-2 activity
during RSV infection leads to a significant inhibition of
RNA transcription, as indicated by the greatly reduced
amount of N gene transcript, although we cannot exclude an
effect on virus uncoating. It is also possible that PGE2
affects other steps of RSV replication, which will require
further investigation in order to be defined. Interestingly, a
different member of the prostaglandin family, PGI2, has
T. Liu et al. / Virology 343 (2005) 12–2420been show to have an antiviral effect in an in vivo model of
RSV infection (Hashimoto et al., 2004). Mice overexpress-
ing PGI2 are protected against RSV-induced lung disease
and have decreased peak viral titers, suggesting that
different eicosanoids may play a different role in viral
replication (Hashimoto et al., 2004).
Inhibition of viral replication is the likely explanation
for the significant reduction we observed in chemokine
gene expression in airway epithelial cells treated with
celecoxib. We have previously shown that viral replication
is necessary for RSV-induced transcription of the chemo-
kines IL-8 and RANTES, as well as for activation of NF-
nB and IRF transcription factors (Garofalo et al., 1996;
Casola et al., 2000, 2001b). However, we cannot exclude a
direct role of AA or eicosanoids, produced during cPLA2
or COX-2 activation, in RSV-induced cellular signaling.
AA release has been shown to be an important mediator
for activation of a variety of transcription factors, including
AP-1, NF-nB, and STATs (Becuwe et al., 2003; Yellaturu
and Rao, 2003). Inhibition of chemokine and other RSV-
induced proinflammatory molecules, by targeting either
cPLA2 or COX-2 activation, could be beneficial in am-
eliorating RSV-induced lung inflammation and clinical
disease, as suggested by the finding that treatment of
cotton rats with indomethacin, a nonspecific COX-2
inhibitor, significantly reduces RSV-induced peribronchial
and perivascular inflammatory infiltrates, as well as
interstitial pneumonitis and alveolitis (Richardson et al.,
2005). Additional studies are needed to better define the
role of cPLA2 and COX-2 activation in RSV-induced lung
inflammatory and immune responses, as potential targets
for treatment of RSV-induced lung disease.Materials and methods
Reagents
Antibodies recognizing 85 kDa cPLA2, h-actin, h-
catenin, and the peroxidase-conjugated anti-rabbit and
anti-goat secondary antibodies were purchased from Santa
Cruz Biotech, Santa Cruz, CA. Antibody to COX-2 was
obtained from Cayman Chemical Company, Ann Arbor, MI.
The chemical inhibitors cycloheximide, bromophenacyl
bromide (BPB), methyl arachidonyl fluorophosphonate
(MAPF), pyrrophenone (PP), indomethacin, celecoxib, and
NS398 were purchased from Calbiochem-EMD Bioscience
Inc., San Diego, CA. Protease Inhibitor Cocktail was
purchased from Sigma.
RSV preparation
The RSV A2 strain was grown in Hep-2 cells and
purified by centrifugation on discontinuous sucrose gra-
dients as described elsewhere (Ueba, 1978). The virus titer
of the purified RSV pools was 8–9 log10 plaque formingunits (PFU)/ml using a methylcellulose plaque assay. No
contaminating cytokines were found in these sucrose-
purified viral preparations (Patel et al., 1995). LPS, assayed
using the limulus hemocyanin agglutination assay, was not
detected. Virus pools were aliquoted, quick-frozen on dry
ice/alcohol, and stored at 70 -C until used.
Cell culture and infection of epithelial cells with RSV
A549, human alveolar type II-like epithelial cells (from
ATCC, Manassas, VA), were maintained in F12K medium
containing 10% (v/v) FBS, 10 mM glutamine, 100 IU/ml
penicillin, and 100 Ag/ml streptomycin. Cell monolayers
were infected with RSV at MOI of 3 (unless otherwise
stated), as described (Garofalo et al., 1996). An equivalent
amount of a 30% sucrose solution was added to uninfected
A549 cells as a control. For simplicity, uninfected cells are
identified as ‘‘control’’ cells throughout the text and in the
figures. When inhibitors were used, A549 cells were
pretreated for 1 h with the inhibitors and then infected with
RSV in the presence of the inhibitors. When inhibitors were
diluted in DMSO, equal amounts of vehicle were added to
untreated cells as a control. Total number of cells, cell
viability, and viral replication, following treatment, were
measured by trypan blue exclusion and by plaque assay,
respectively. We did not observe cellular toxicity/cell death
at any of the inhibitors concentration used for the described
experiments.
ELISAs
Immunoreactive PGE2, IL-8, and RANTES were meas-
ured by double antibody ELISA kits (R&D Systems,
Minneapolis, MN) following the manufacturer’s protocol.
Western blotting
RSV-infected and control cells were lysed by adding ice-
cold lysis buffer (50 mMTris–HCl, pH 7.4, 150 mMNaCl, 1
mM EGTA, 0.25% sodium deoxycholate, 1 mM Na3VO4, 1
mM NaF, 1% Triton X-100, and 1 Ag/ml of aprotinin,
leupeptin, and pepstatin). After incubation on ice for 10 min,
the lysates were collected, and detergent insoluble materials
were removed by centrifugation at 4 -C at 14,000  g. Cell
lysates (50 Ag per sample) were then boiled in 2 Laemmli
buffer for 2 min and resolved on SDS-PAGE. Proteins were
transferred for 6 h onto Hybond-ECL nitrocellulose mem-
brane (Amersham Pharmacia Biotech), and nonspecific
binding sites were blocked by immersing the membrane in
blocking solution TBS–Tween (TBST, 10 mM Tris–HCl,
pH 7.6, 150 mM NaCl, 0.05% Tween-20) containing 5%
skim milk powder for 30 min. After short wash in TBST, the
membranes were incubated with the primary antibody over-
night at 4 -C, followed by the peroxidase-conjugated
secondary antibody, diluted 1:10,000 in TBST for 30 min
at room temperature. After washing, proteins were detected
T. Liu et al. / Virology 343 (2005) 12–24 21using ECL (Amersham Pharmacia Biotech) according to
manufacturer’s protocol.
Northern blot
Total RNAwas extracted from control and infected A549
cells by the acid guanidium thiocyanate-phenol chloroform
method (Chomczynski and Sacchi, 1987). Twenty micro-
grams of RNA was fractionated on a 1.2% agarose–
formaldehyde gel, transferred to nylon membranes, and
hybridized to a radiolabeled RSV N cDNA (Liu et al., 2004)
or COX-2 cDNA (a generous gift of Dr. R. Mifflin, UTMB,
Galveston, TX), as previously described (Casola et al.,
2001b). After washing, membranes were exposed for
autoradiography using Kodak XAR film at 70 -C, using
intensifying screens. After exposure, membranes were
stripped and rehybridized with a h-actin probe. For COX-
2 quantitative real-time PCR (Q-RT-PCR), Applied Bio-
systems assays-on-demand 20 mix of primers and Taq-
Man MGB probes (FAM-dye labeled) for target genes and
18S rRNA (VIC-dye labeled probe) TaqMan assay reagent
(P/N 4319413E) for controls were used. Separate tubes
(singleplex) one-step RT-PCR was performed with 80 ng
RNA for both target genes and endogenous control. The
cycling parameters for one-step RT-PCR were: reverse
transcription 48 -C for 30 min, AmpliTaq activation 95 -C
for 10 min, denaturation 95 -C for 15 s, and annealing/
extension 60 -C for 1 min (repeat 30 times) on ABI7000.
Duplicate CT values were analyzed in Microsoft Excel
using the comparative CT (DDCT) method as described by
the manufacturer (Applied Biosystems). The amount of
target (2DDCT) was obtained by normalizing to endogenous
reference (18S) sample.
[3H]Arachidonic acid release
Cells were grown to confluency in 24-well plates and
labeled in serum-free medium supplemented with 0.5 ACi
[3H]arachidonic acid overnight. Radioactive medium was
then discarded, cells were washed several times with serum-
free medium and infected with RSV. At different times post-
infection, cell supernatants were carefully collected to avoid
cell disruption and assessed for [3H]arachidonic acid release
by liquid scintillation counting.
Preparation of cytosolic and membrane fractions
Control or RSV-infected A549 cells were rinsed twice
with sterile PBS and digested with 1 trypsin/EDTA,
washed and centrifuged two times with cold Ca2+- and
Mg2+-free Hank’s Balanced Salt Solution HBSS ().
Cells were transferred to ice-cold homogenization buffer
(50 mM Tris–HCl pH 8.0, 1 mM EDTA, 1 mM EGTA,
20% glycerol, freshly added 1 mM DTT, and Protease
Inhibitor Cocktail 1:100 dilution). Cell suspensions were
then disrupted by sonication on ice using BransonSonicator (15–20 second cycle for 4 cycles at 20% duty
cycle). The sonicate was centrifuged for 5 min at 4 -C at
1000  g to remove unbroken cell and debris. This low
speed supernatant, designated as crude homogenate, was
subsequently centrifuged at 100,000  g at 4 -C for 1 h.
The high speed supernatant was designated as cytosolic
fraction. The high speed pellet, representing the mem-
brane fraction, was washed several times with ice-cold
buffer containing 0.9% NaCl to remove cytosolic protein
contaminant and resuspended in 500 Al of ice-cold
homogenization buffer containing 0.1% Triton X-100.
The pellet was then sonicated on ice for 15 s for 4 cycles.
The cytosol and membrane fractions were aliquoted and
stored at 80 -C until used for PLA2 assay. Protein
concentration was determined using Protein Reagent, Bio-
Rad, Hercules, CA.
Phospholipase A2 assay
cPLA2 activity was assayed according to the method
described by Neagos et al. (1993) by quantification of the
amount of free radiolabeled AA hydrolyzed from sn-2-
[14C]-arachidonyl phosphatidyl-ethanolamine (52 mCi/
mmol; NEN, Dupont). 100,000 dpm for each sample was
taken in a conical glass stoppered tube, evaporated to
dryness under a stream of N2 gas to completely remove
organic solvent, suspended in ice-cold 50 mM Tris–HCl
(pH 8.0) buffer, and sonicated for 2–3 min to prepare
micelle of liposomes and kept on ice. 400 to 500 Ag protein
of either cytoplasmic or membrane fractions was added in
100 Al of assay buffer (50 mM Tris–HCL, pH 8.0, 0.5 mg/
ml BSA, 0.5 mM EDTA, 20% glycerol (vol/vol) 10.5 mM
CaCl2) and pre-incubated at 37 -C for 5 min. The reaction
was started by addition of substrate followed by gentle
vortexing and incubation for 15 min at 37 -C with constant
gentle shaking. One milliliter of chloroform–methanol
mixture (2:1, vol/vol), containing 1% acetic acid, was
added to stop the reaction and immediately vortexed
vigorously for 2–3 min and then centrifuged at 2500 rpm
for 5 min. After centrifugation, the lower chloroform phase
containing the AA was transferred carefully into another
tube without disturbing the upper phase and interphase. The
remaining aqueous phase was washed with 0.5 ml chloro-
form: methanol mixture and the combined organic phase
were evaporated to dryness under N2 gas, and the tubes
covered and kept at 20 -C. Free AA was separated by
thin-layer chromatography on silica gel plates using a
solvent system of heptane/isopropyl ether/acetic acid
(15:10:1 v/v), and the corresponding radioactivity in each
of the spots was determined by scintillation counting. In
each assay, hydrolysis was corrected for that which
occurred in the absence of added protein sample. Percent
hydrolysis was determined by the free AA released, and
PLA2 activity expressed as dpm/mg protein/min. For each
experiment, results from triplicate assays were averaged to
yield a single value.
T. Liu et al. / Virology 343 (2005) 12–2422Ribonuclease protection assay (RPA)
Control or RSV-infected A549 were harvested at different
time points for total RNA extraction. Chemokine mRNA
expression was determined using the multiprobe template
hCK-5 of the RiboQuant kit (Pharmingen, San Diego, CA),
as previously described (Haeberle et al., 2004). Briefly, the
probe was labeled with a-[32P]-UTP (3000 Ci/mmol, 10 ACi/
Al; Du Pont NEN Research Products, Boston, MA) using a
T7 polymerase. After overnight hybridization with 2 Ag of
total RNA and RNA digestion, the samples were treated with
proteinase K–SDS mixture, extracted by phenol chloroform,
ethanol-precipitated, and loaded on a sequencing gel. Gels
were dried and exposed to XAR film for autoradiography or
PhosphoImager cassette for quantitation.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts of uninfected and infected cells were
prepared using hypotonic/nonionic detergent lysis, as
previously described (Casola et al., 2000). After normal-
ization, nuclear proteins were used to bind to duplex
oligonucleotides corresponding to either the RANTES ISRE
or the IL-8 NF-nB binding sites, as previously described
(Casola et al., 2000, 2001a). DNA-binding reactions
contained 10–15 Ag nuclear proteins, 5% glycerol, 12
mM HEPES, 80 mM NaCl, 5 mM DTT, 5 mM Mg2Cl, 0.5
mM EDTA, 1 Ag of poly dI-dC, and 40,000 cpm of 32P-
labeled double-stranded oligonucleotide in a total volume of
20 Al. The nuclear proteins were incubated with the probe
for 15 min at room temperature and then fractionated by 6%
nondenaturing polyacrylamide gels (PAGE) in TBE buffer
(22 mM Tris–HCl, 22 mM boric acid, 0.25 mM EDTA, pH
8). After electrophoretic separation, gels were dried and
exposed for autoradiography using Kodak XAR film at 70
-C using intensifying screens.Acknowledgments
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